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interventions, optimal allocation decisions are derived,
hypothetically assuming a market context.
RESULTS: vNM utility functions are developed for the
alternative treatments and a “no treatment” option (T0)
on the basis of outcome and probability data from clini-
cal research. Utilities of procedures and outcomes can be
identiﬁed empirically. This requires a preference ordering
of treatment alternatives and MSG questions relating to
hypothetical treatments. The number of MSG questions
and hypothetical treatments (n-2) depends on the number
of vNM variables (n). This procedure identiﬁes the ratio
of marginal utilities of T1 and T2, dT2/dT1. The inclu-
sion of relative prices of T1 and T2, pT1/pT2, into the
model allows the prediction of utility-based treatment
choices and the application of the model in resource 
allocation.
CONCLUSIONS: The main advantages of this model are
its ability to predict utility-based decisions incorporating
risk preferences and to avoid the need for methodologi-
cally delicate techniques such as sensitivity analysis and
discounting. The practical beneﬁts of this approach
remain to be determined within empirical evaluations.
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Technological advances have resulted in Electronic Data
Collection (EDC) increasingly replacing traditional paper
and pencil questionnaire data collection of clinical trial
data, including Patient Reported Outcomes (PRO). Our
objective was to assess EDC compared to traditional
methods of PRO data collection to assist in selecting a
method.
METHODS: A literature search identiﬁed EDC-related
publications within the last 5 years; a web search identi-
ﬁed regulatory and institutional guidance documents.
RESULTS: Of 584 articles identiﬁed, approximately 60
articles using EDC to assess PRO data were selected for
full review. Four forms of EDC were identiﬁed: personal
digital assistants (PDAs), personal computers (PCs), inter-
active voice response (IVR) systems, and electronic 
mail. PDAs, PCs, and IVR may offer higher data quality
than pencil and paper; data entry can be immediate, logic
checks can be incorporated, thus reducing the number of
data queries. Compliance with data collection protocols
has been shown to be higher using EDC and evidence
indicates patients and clinicians prefer it. All methods
require back-up and security procedures to ensure data
integrity. Studies examining EDC costs have consistently
found paper and pencil methods more expensive espe-
cially as volume increases. PDAs, PCs, and IVR have been
used in clinical trials to assess PROs but email lacks
anonymity thereby making it unsuitable. Ecological
momentary assessment (EMA) is real-time or scheduled
assessment of PRO; patients are prompted to complete
assessments in their current environment. EDC facili-
tates EMA data collection and enhances data volume and
quality. The FDA requires extensive documentation of
audit trails, but has not released requirements for EDC
procedures.
CONCLUSIONS: EDC demonstrates advantages for the
collection of high quality data quickly. As new technolo-
gies proliferate, clinical trials can take advantage of EDC
to enhance data quality and reduce trial-related costs with
precautions to ensure data security.
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Patient-generated outcomes attempt to capture the indi-
vidualistic nature of quality of life. Although this is an
attractive concept, a critical review of these instruments
is needed to assess their applicability in a clinical trial
setting.
OBJECTIVE: To provide a critical review of four patient-
generated quality of life instruments: Patient-Generated
Index (PGI), Schedule for the Evaluation of Individual
Quality of Life (SEIQoL), Repertory Grid, and Asthma
Quality of Life Questionnaire (AQLQ).
METHODS: We conducted a systematic literature review
of available computerized databases, the Quality of Life
Research Journal and consulted experts in the ﬁeld. We
abstracted data from the studies and constructed a matrix
comparing the four instruments based on their psycho-
metric properties and current use in quality of life
research.
RESULTS: The PGI and SEIQoL have been shown to be
reliable and valid in several different patient populations
and disease states; however, neither have been used in a
clinical trial. The SEIQoL-DW, in addition, has been
shown to be practical and acceptable to patients. The
Repertory Grid has been shown to be reliable, valid and
practical, but has only been used in one observational
study. The AQLQ is a disease-speciﬁc instrument that is
only partially patient-generated. It has not only shown to
be reliable, valid and practical, but has also been used in
clinical trials as a sole measure of quality of life.
CONCLUSION: Patient-generated outcomes may not be
generally useful in a clinical trial setting. However, hybrid
instruments, such as the AQLQ, may be applicable in a
clinical trial setting. The primary role of patient-
generated outcome measures is as an adjunct measure or
to guide individual patient treatment decisions.
